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ABSTRACT 
 
Melanoma is a malignant proliferative disease originated from melanocyte transformations, 
which are characterized by a high metastatic rate and mortality. Advances in Nanotechnology 
have provided useful new approaches and tools for antitumor chemotherapy. The aim of this 
study was to investigate the molecular mechanisms underlying chitosan nanoparticles 
containing S-nitroso-mercaptosuccinic acid (S-nitroso-MSA-CS)-induced cytotoxicity in 
melanoma cells. S-nitroso-MSA-CS induced concentration-dependent cell death against B16-
F10 tumor cells, whereas non-nitroso nanoparticles (CS or MSA-CS) did not induce 
significant cytotoxicity. Additionally, melanoma cells were more sensitive to cell death than 
normal melanocytes. S-nitroso-MSA-CS-induced cytotoxicity exhibited features of caspase-
dependent apoptosis and it was associated with oxidative stress, characterized by increased 
mitochondrial superoxide production and oxidation of protein thiol groups. In addition, 
tyrosine nitration and cysteine S-nitrosylation of amino acid residues in cellular proteins were 
observed. The potential use of these nanoparticles in antitumor chemotherapy of melanoma is 
discussed. 
Keywords: Cytotoxicity, Melanoma, Nanoparticles, Nitric Oxide, S-nitrosothiol. 
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Graphical Table of Contents. Scheme illustrating molecular alterations related to cell death 
elicited by S-nitroso-MSA-CS nanoparticles in melanoma.   
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INTRODUCTION 
Skin cancer is the most common type of cancer in Caucasian populations,
[1]
 and the 
clinical classifications are based on the tumor origin and divided into non-melanoma skin 
cancer and melanoma.
[2]
 Melanoma arises from cumulative abnormalities in melanocytes in 
response to ultraviolet-induced DNA damage,
 
resulting in genetic mutations that support their 
malignancy through stimulation of blood vessel growth, evasion of the immune response and 
apoptosis, tumor invasion and metastasis.
[3]
 Specific gene mutations are associated with an 
increased risk of melanoma, e.g., the substitution of valine (V) to glutamic acid (E) at position 
600 in the BRAF gene (BRAF V600E), which is reported in 40-50% of melanoma cases.
[4]
 
Early diagnosis of melanoma is crucial for the effectiveness of treatment and favorable 
prognosis of patients. Available tools for melanoma treatment include surgical excision, 
immunotherapy, radiotherapy, and chemotherapy.
[5]
 Immunotherapy (ipilimumab) or targeted 
therapy (vemurafenib) are the main chemotherapeutic approaches used for the treatment of 
metastatic melanoma when the BRAF V600E mutation is expressed.
[6]
 Antitumor drugs have 
serious side effects, including hypotension, neutropenia, gastrointestinal and skin 
dysfunctions, and hair loss.
[6]
 Specifically, for the treatment of melanoma, toxic side effects 
described for vemurafenib include photosensitivity, follicular hyperkeratosis, maculopapular 
rash, arthralgia, QT prolongation, and others.
[7]
 For ipilimumab, the most common side 
effects described include diarrhea, nausea, constipation, abdominal pain, vomiting, vitiligo 
and dermatitis,
[8]
 although more deleterious side effects had already been described such as 
hepatitis,
[9]
 enterocolitis,
[10]
 pancreatitis and nephritis.
[11]
 New approaches are emerging in the 
drug discovery field due to the recent advances in Nanotechnology, providing additional 
opportunities to overcome drug resistance and toxicity, which are considered the major 
limitations in melanoma chemotherapy.
[12]
 These nanotechnological strategies involve the 
development of several types of nanostructured drug delivery systems focused on the 
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improvement of the specificity and efficacy of chemotherapeutic drugs, increasing the drug 
concentration inside the tumor mass, and decreasing toxicity of chemotherapy.
[13]
 
Polymeric nanoparticles form colloidal systems, which are potentially useful for 
carrying drugs with low water solubility and/or controlling drug release, providing increased 
stability and drug delivery profile.
[14]
 Therefore, chitosan, which is a biocompatible, nontoxic, 
and biodegradable polymer with pharmaceutical applications, has been widely used for 
nanoparticle preparation.
[15]
 It is well known that nitric oxide (NO) is involved in various 
physiological cellular processes such as differentiation and apoptosis.
[16]
 At high 
concentrations, NO exhibit anticancer properties;
[17]
 however, due to its short half-life in 
biological environments (1-5 s), it becomes difficult to reach these antitumor 
concentrations.
[18]
 To increase their bioavailability and in vivo stability, low molecular weight 
molecules capable of acting as NO donors, such as S-nitrosothiols (RSNOs), have been 
developed.
[19]
 Considering that NO-releasing polymeric nanomaterials are emerging as a 
promising strategy in cancer chemotherapy,
[20]
 biocompatible chitosan nanoparticles (CS) 
were synthesized and used to encapsulate low molecular weight mercaptosuccinic acid 
(MSA), a thiol-containing small molecule. Free thiol groups on mercaptosuccinic chitosan 
nanoparticles (MSA-CS) were nitrosated to form S-nitroso-MSA-containing chitosan 
nanoparticles (S-nitroso-MSA-CS). S-nitroso-MSA belongs to the class of RSNOs and acts as 
a NO donor. S-nitroso-MSA-CS was previously synthesized and characterized and had its 
cytotoxicity screened in different cancer cells lines.
[21]
 Additionally, the transdermal NO 
delivery in human skin upon dermatological application of S-nitroso-MSA-CS was 
demonstrated.
[22] 
Here, we investigated the underlying mechanisms of cytotoxicity of S-
nitroso-MSA-CS in an in vitro melanoma model. 
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EXPERIMENTAL SECTION 
Synthesis of MSA-CS and nitrosation to produce S-nitroso-MSA-CS  
CS nanoparticles were prepared using an ionotropic gelation process.
[23]
 Briefly, 0.1 g of CS 
was solubilized in 0.1 L of 1% acetic acid plus 66.7 mM MSA. Under magnetic stirring, 5.0 
mL of 0.6 mg/mL sodium tripolyphosphate was added dropwise in 15 mL of MSA-CS 
suspension. The final mixture was stirred for 45 minutes at 25°C to form the aqueous 
suspension of CS (1.0 mg/L of CS) containing 7.5 mg/mL of MSA (which corresponds to 50 
mM MSA). Control CS was prepared without the addition of MSA. The thiol groups of MSA-
CS were nitrosated by reacting with an equimolar amount of sodium nitrite in acidified 
medium, as previous described.
[24]
 This solution was homogenized, protected from light, 
incubated for 30 min, and used immediately in experiments. The formation of S-nitroso-
MSA-CS was confirmed by the detection of S-NO characteristic absorption bands at 336 and 
545 nm. 
 
Cell culture and standard incubation conditions with NPs  
Cell line B16-F10 was purchased from the Rio de Janeiro Cell Bank (BCRJ 0046) (murine 
melanoma), and Melan-A (murine normal melanocytes) was generously provided by Prof. 
Miriam Galvonas Jasiulionis (UNIFESP) in 2015. Consequently, the authors performed no 
additional authentication. All cell lines were tested to be mycoplasma-free by indirect staining 
with Hoechst 33258 (Thermo Fisher Scientific, USA) and were used within 3 months of 
thawing the frozen stock. Cells were grown in DMEM (Dulbecco's Modified Eagle's medium) 
high glucose medium (Sigma-Aldrich, USA) pH 7.2, supplemented with 10% fetal bovine 
serum (Gibco, Invitrogen, USA), 100 U/mL penicillin and 100 µg/mL streptomycin, in a 5% 
CO2 atmosphere at 37°C (Panasonic MCO-19AIC, Japan). For experiments, cells were 
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detached, centrifuged (160×g for 10 minutes), and suspended in supplemented DMEM 
medium. B16-F10 cells (5.26×10
4
 cells/cm
2
) were added to microplates for 24 h for cell 
adhesion. After, S-nitroso-MSA-CS (20 and 40 µg/mL) was added and incubated for 
additional 24 h. 
 
Cytotoxicity assays  
The cytotoxicity of NPs was screened by the trypan blue dye exclusion assay in B16-F10 
melanoma cells and melanocytes Melan-A. Compounds were added at increasing 
concentrations (5.0, 10, 20, and 40 µg/mL) and incubated for 24 h. After this, trypan blue was 
added 0.016% (w/v) and cells were counted using a Neubauer chamber. Additionally, the 
effects of modulators of cell death induced by S-nitroso-MSA-CS were evaluated by the MTT 
reduction test. Thus, after an incubation period, 0.25 mg/mL MTT was added and incubated 
for 4 h. Then, 0.1 mL of 10% SDS was added, incubated overnight, and plates were read at 
570 nm/620 nm (Biochrom Asys Expert Plus Microplate Reader, Biochrom Ltd., UK). The 
modulators [50 µM Boc-D-FMK (Sigma-Aldrich, USA), 5 µM MY5445 (Tocris Bioscience, 
USA), 100 µM PTIO (Sigma-Aldrich, USA)] were pre-incubated 1 hour before the addition 
of the nanoparticles. Cell viability in both assays was calculated in relation to the control 
(absence of NPs), which was considered as 100%. 
 
Lactate dehydrogenase (LDH) release 
After a standard incubation, cells were detached and centrifuged (160×g for 10 minutes) and 
supernatants were kept at 4°C. LDH activity released by cells was determined through NADH 
oxidation measured using the LDH assay kit according to the manufacturer instructions 
(Labtest Diagnostica SA, Brazil). Triton X-100 (0.2%) was used as positive control. 
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Annexin V-FITC/PI double staining flow cytometry analysis 
After a standard incubation, cells were detached, centrifuged (160×g for 10 minutes) and 
suspended in 50 µL of binding buffer
[25]
 plus 5.0 µL Annexin V-FITC (BD Biosciences, 
USA) and 5.0 µL PI (BD Biosciences, USA). The mixture was incubated in the dark at room 
temperature for 20 minutes. After addition of 0.3 mL of binding buffer, fluorescence emission 
was measured with a FACSCanto II Flow Cytometer (BD Biosciences), acquiring 10,000 
events per sample using a Coherent® Sapphire™ 488-20 solid state blue laser with an 
excitation at 488 nm, dichroic mirror 502 LP, bandpass filter 530/30 for the FITC 
fluorescence channel and dichroic mirror 556 LP, bandpass filter 585/42 for the PI 
fluorescence channel. Data analysis and graphs was completed using Flow Jo vX.0.7 software 
(Ashland, USA). 
    
Active caspase 3 
Caspase 3 was measured by flow cytometry using a monoclonal antibody against the active 
form. After a standard incubation, cells were fixed with 2% paraformaldehyde in PBS for 
30 min and permeabilized with 0.01% saponin in PBS for 15 min at room temperature. Cells 
were then collected and incubated with 10 µL anti-active-caspase-3 monoclonal antibody 
conjugated with FITC #559565 (BD-Pharmingen, USA). After a 40-min incubation at 37 °C, 
the fluorescence emission was analyzed acquiring 10,000 events per sample using blue laser 
excitation (488 nm), dichroic mirror 502 LP, bandpass filter 530/30 and the FITC 
fluorescence channel with a FACSCanto II Flow Cytometer. Data analysis and graphs were 
completed using Flow Jo vX.0.7 software. 
 
Reduced protein thiol content  
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Total protein −SH groups were quantified using 5,5′-dithiobis (2-nitrobenzoic) acid (DTNB). 
After a standard incubation, cells were detached and centrifuged for 10 min at 700×g. The 
pellet was treated with 0.2 ml of 6% trichloroacetic acid and centrifuged at 6000×g for 15 min 
to precipitate the proteins. This precipitate was suspended with 1 ml of 0.5 M potassium 
phosphate buffer pH 7.6 by vortexing. After the addition of 0.1 mM DTNB, absorbance was 
determined at 412 nm (UV-Visible Spectrophotometer UV-1800, Shimadzu, Japan). 
 
Reactive oxygen species (ROS) production 
After a standard incubation, cells were collected and loaded with 5 µM MitoSOX™ Red or 5 
µM CM-H2DCFDA (Life Technologies, Invitrogen, USA) for 30 minutes. As positive 
controls, 20 µM antimycin A and 100 µM hydrogen peroxide (H2O2) were used. End time 
fluorescence emission was measured using the blue laser with an excitation at 488 nm, 
dichroic mirror 502 LP, bandpass filter, 530/30 FITC fluorescence channel for CM-
H2DCFDA and the dichroic mirror 556 LP, bandpass filter 585/42 for the PI fluorescence 
channel for MitoSOX™ Red with a FACSCanto II Flow Cytometer. Data analysis and graphs 
was completed using Flow Jo vX.0.7 software. Alternatively, continuous ROS production was 
evaluated. After incubation with S-nitroso-MSA-CS for 2 h, cells were loaded with 5 µM 
CM-H2DCFDA for 30 min and fluorescence was kinetically recorded for 120 minutes in a 
microplate reader Synergy HT (Biotek Instruments, USA) at 485 nm and 528 nm excitation 
and emission, respectively. As positive control, 2 mM t-BOOH (Sigma-Aldrich, USA) was 
used, and 100 U/mL PEGylated catalase (Sigma-Aldrich, USA) was used to distinguish the 
fluorescence signal attributed exclusively to the peroxide production. 
 
Detection of cysteine S-nitrosylation and tyrosine 3-nitration 
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After a standard incubation, cells were fixed with 2% paraformaldehyde in PBS for 30 min 
and permeabilized with 0.01% saponin in PBS for 15 min at room temperature. Cells were 
then incubated overnight with the rabbit polyclonal anti-nitrotyrosine primary antibody 
(#9691, Cell Signaling, USA) (1:200) and mouse monoclonal S-nitrosocysteine primary 
antibody (#ab94930, Abcam, UK) (1:200). After, secondary antibodies − goat anti-Rabbit IgG 
(H+L) with Alexa Fluor 488 (#A11034, Cell Signaling, USA) (1:500) or goat Anti-Mouse 
IgG with FITC (#F8521, Sigma-Aldrich, USA) (1:500) − were incubated for one hour at room 
temperature. Nuclei were stained with 5 nM SlowFade® Gold Antifade Mountant with DAPI 
(Thermo Fisher Scientific, USA) for 15 min. Fluorescence emissions were acquired with a 
widefield fluorescence microscopy system Leica AF6000 (Leica Microsystems, Germany) 
using the set of cube filters A4 (Ex: 360/40, dichroic mirror: 400 nm: Filter BP: 470/40) and 
L5 (Ex: 480/40; dichroic mirror: 505 nm; BP filter: 527/30), objective lens HCX APO U-V-I 
100 x/1.3 OIL, and camera DFC365FX. 
 
Statistical analyses 
Values were obtained from at least three independent experiments run in triplicate. Data were 
expressed as the mean ± SEM, and statistical analyses were performed by a one-way analysis 
of variance (followed by a Tukey post hoc test) with significance defined as *p<0.05, 
**p<0.01, *** p<0.001. 
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RESULTS 
Enhanced and selective cytotoxicity of S-nitroso-MSA-CS in melanoma B16-F10 cells 
The effects of S-nitroso-mercaptosuccinic acid containing chitosan nanoparticles (S-nitroso-
MSA-CS) (Fig. 1A) on B16-F10 and Melan-A cell viability were screened by the trypan blue 
exclusion assay. S-nitroso-MSA-CS exhibited high cytotoxicity against the B16-F10 tumor 
cell line in a concentration-dependent manner after 24 h of incubation. Such cytotoxicity was 
higher in tumor cells than in normal melanocytes (Fig. 1B). Additionally, non-nitroso MSA 
chitosan nanoparticles (MSA-CS), empty chitosan nanoparticles (CS), free S-nitroso-MSA, 
and MSA (in the same molar ratio used in Fig. 1B) were evaluated in B16-F10 cells and no 
significant cytotoxicity was achieved, showing the dependence of the nanoparticle structure 
(Fig. 1c). In flow cytometry, the frontal dispersion of the laser (forward scatter, FSC) gives 
information about the relative cell size and the lateral dispersion (side scatter, SSC) is related 
to granularity or complexity of the cell. S-nitroso-MSA-CS decreased cell size and increased 
the granularity of melanoma cells, defining a ‘dead’ population (Fig. 1D), which was 
dependent on concentration (Fig. 1E). Additionally, S-nitroso-MSA-CS induced the loss of 
normal morphology, membrane blebbing, cell shrinkage, emission of plasma membrane 
projections, and disruption. The loss of adhesion with the external matrix and neighboring 
cells was also observed (Fig. 1F). 
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Fig. 1. Enhanced and selective cytotoxicity of S-nitroso-MSA-CS in melanoma B16-F10 
cells. (A) Schematic representation of the S-nitroso-MSA-CS nanoparticle structure. (B) 
Effects of S-nitroso-MSA-CS on B16-F10 (gray line) and Melan-A (black line) cell viability 
assessed by trypan blue assay. ***(p<0.001) and **(p<0.01) indicates a difference from 
Melan-A at each concentration. The results presented as the mean ± SEM of at least three 
independent experiments performed in triplicate. (C) Effects of MSA-CS (dashed line), CS 
(dotted line), free S-nitroso-MSA (black line), and free MSA (gray line) on B16-F10 cell 
viability. The results presented as the mean ± SEM of at least three independent experiments 
performed in triplicate. (D) Changes in cell size and granularity (FSC x SSC parameters). 
Representative dot plots of at least three independent experiments performed in duplicate. (E) 
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Quantification of live and dead cells based on FSC and SSC parameters. The results presented 
as the mean ± SEM of at least three independent experiments performed in triplicate. (F) 
Morphological alterations of B16-F10 cells assessed by optical microscopy (400× 
magnification, scale bar 100 µm). Representative images of at least two independent 
experiments performed in duplicate. 
S-nitroso-MSA-CS induced apoptosis in melanoma cells 
To obtain a better understanding of S-nitroso-MSA-CS-induced cell death, molecular markers 
of apoptosis and necrosis were evaluated. Annexin V-FITC/PI double staining flow cytometry 
revealed the predominance of double stained B16-F10 cells (annexin V
+
/PI
+
), indicative of 
late apoptosis (Fig. 2A). Since the dot plot graph is one representative experiment, the 
quantification of apoptotic cells (annexin V
+
), considering all replicates was presented (Fig. 
2B). Additionally, the activation of effector caspase 3 during S-nitroso-MSA-CS-induced cell 
death was shown (Fig. 2C and 2D). The cell-permeable irreversible general caspase inhibitor 
Boc-D-FMK also prevented cell death (Fig. 2E), corroborating the participation of caspases. 
The pre-incubation of B16-F10 cells with necrostatin-1 (Sigma-Aldrich #N9037) and IM-54 
(Sigma-Aldrich #SLM0412), inhibitors of necroptosis and necrosis, respectively, did not 
prevent the S-nitroso-MSA-CS-induced cytotoxicity (Fig. 2F and 2G). In accordance, loss of 
plasma membrane integrity induced by S-nitroso-MSA-CS was not observed, as evaluated 
through the absence of LDH release by the cells (Fig. 2H). Thus, S-nitroso-MSA-CS induced 
caspase-dependent apoptosis in melanoma cells. 
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Fig. 2. S-nitroso-MSA-CS induced apoptosis in B16-F10 melanoma cells. (A) Cell death 
profile achieved by annexin V-FITC/PI double staining flow cytometry analysis. 
Representative dot plot of at least three independent experiments performed in duplicate. (B) 
Quantification of apoptotic (annexin V-FITC positive) cells. The results presented as the 
mean ± SEM of at least three independent experiments performed in duplicate. ***(p<0.001) 
indicates a difference from control (absence of NPs). (C) Activation of caspase-3. Gray line 
(absence of NPs), black line (S-nitroso-MSA-CS 20 µg/mL), dashed black line (S-nitroso-
MSA-CS 40 µg/mL). Representative histogram of at least three independent experiments 
performed in duplicate. (D) Quantification of active caspase 3. Results presented as the mean 
± SEM of at least three independent experiments performed in duplicate. ***(p<0.001) 
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indicates a difference from control (absence of NPs). Effect of caspase inhibitors on the S-
nitroso-MSA-CS-induced cytotoxicity: 50 µM Boc-D-FMK (E), 10 µM IM-54 (F), and 60 
µM necrostatin-1 (G). Results presented as the mean ± SEM of at least three independent 
experiments performed in triplicate. Statistical differences are indicated. (H) Estimation of 
LDH released. LDH activity in control (absence of NPs) was 137.61 ± 32.38 (U/L) and in 
Triton X-100 was 1036.15 ± 40.47 (U/L). The results presented as the mean ± SEM of at least 
three independent experiments performed in triplicate. 
Increased oxidative stress induced by S-nitroso-MSA-CS 
A general view of the cellular reactive oxygen species (ROS) production can be achieved by 
the assessment of oxidized dichlorofluorescein (DCF) fluorescence emission.
[26]
 Thus, B16-
F10 melanoma cells were incubated with S-nitroso-MSA-CS for 24 h and loaded with CM-
H2DCFDA. As observed in Fig. 3A, S-nitroso-MSA-CS at 20 and 40 µg/mL (dashed and 
black lines, respectively) increased ROS generation in B16-F10 melanoma cells. Hydrogen 
peroxide (H2O2) was used as a positive control (dotted line). The fluorescence quantification 
of replicates is presented in Fig. 3B. Considering the relative lack of specificity of this 
fluorophore to identify a specific free radical type, a kinetic measurement of ROS production 
elicited by S-nitroso-MSA-CS (dashed lines) with CM-H2DCFDA was performed for 120 
minutes in the presence of catalase conjugated with polyethylene glycol (PEG-CAT, solid 
lines) (Fig. 3C). The quantification of DCF fluorescence emission at 120 minutes revealed 
that part of the DCF oxidation at 20 µg/mL S-nitroso-MSA-CS was attributed to the peroxide 
production but at 40 µg/mL S-nitroso-MSA-CS PEG-CAT did not suppress the emission of 
fluorescence (Fig. 3D), indicating that the radical production profile is different depending on 
the NPs concentration. Since H2O2 can be formed by dismutation of superoxide anions 
produced by mitochondria, we also evaluated the mitochondrial superoxide generation after a 
24 h incubation with NPs using MitoSOX™ Red. As expected, S-nitroso-MSA-CS also 
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increased the generation of superoxide anion radicals by mitochondria in a concentration 
dependent fashion (Fig. 3E and 3F). Antimycin A, an inhibitor of the mitochondrial 
respiratory complex III
[27]
 was used as positive control (Fig. 3E, dotted line). This increased 
radical production induced by S-nitroso-MSA-CS was accompanied by oxidation of the thiol 
group of proteins (Fig. 3G).  
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Fig. 3. Oxidative stress in B16-F10 melanoma cells exposed to S-nitroso-MSA-CS. (A) 
Representative Histograms of DCF fluorescence obtained by flow cytometry. Gray line 
(absence of NPs), dotted black line (100 µM H2O2), black line (S-nitroso-MSA-CS 20 
µg/mL), dashed black line (S-nitroso-MSA-CS 40 µg/mL). (B) Quantification of DCF 
fluorescence considering replicates. The results presented as the mean ± SEM of at least three 
independent experiments performed in duplicate. ***(p<0.001) indicates a difference from 
control (absence of NPs). (C) Kinetic measurement of DCF fluorescence. Representative plot 
of DCFDA fluorescence intensity read at 120 minutes of at least two independent experiments 
performed in triplicate. (D) Quantification of DCF fluorescence from kinetics at t=120 
minutes. ***(p<0.001) indicates a difference from control (absence of NPs). The results 
presented as the mean ± SEM of at least two independent experiments performed in triplicate. 
(E) Representative histogramS of MitoSOX Red fluorescence obtained by flow cytometry. 
Gray line (absence of NPs), dotted black line (20 µM antimycin A), black line (S-nitroso-
MSA-CS 20 µg/mL), dashed black line (S-nitroso-MSA-CS 40 µg/mL). (F) Quantification of 
MitoSOX Red fluorescence considering replicates. The results presented as the mean ± SEM 
of at least three independent experiments performed in duplicate. ***(p<0.001) indicates a 
difference from control (absence of NPs). (G) Reduced thiol content in cellular proteins. The 
results presented as the mean ± SEM of at least three independent experiments performed in 
triplicate. ***Different from control (absence of NPs) in panels B, F, and G.  
Cysteine S-nitrosylation and tyrosine nitration promoted by S-nitroso-MSA-CS 
The incubation of B16-F10 melanoma cells with S-nitroso-MSA-CS (20 and 40 µg/mL) 
resulted in an increased formation of 3-nitrotyrosine (Fig. 4A) and S-nitrosocysteine (Fig. 4B) 
in a concentration dependent manner. To evaluate whether these observed effects were due to 
NO released by S-nitroso-MSA-CS, cells were pretreated with the NO scavenger PTIO (Fig. 
4C) and with an inhibitor of cyclic GMP phosphodiesterase MY5445 (Fig. 4D). Both 
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modulators were not able to change the cytotoxicity exerted by S-nitroso-MSA-CS, which 
provided strong evidence that the protein modifications were not promoted by free cytosolic 
NO released from the nanoparticles. 
 
Fig. 4. S-nitrosylation and tyrosine nitration of cellular proteins promoted by S-nitroso-
MSA-CS. Indirect immunofluorescence with anti-nitrotyrosine (A) and anti-S-nitrosocysteine 
antibodies (B), with the respective quantification of fluorescence presented on right. 
Magnification 1000×, scale bars 50 µm. ***(p<0.001) indicates a difference from control 
(absence of NPs). Effects of 100 µM PTIO (C) and 5 µM MY5445 (D) on the S-nitroso-
MSA-CS induced cytotoxicity. The results presented as the mean ± SEM of at least three 
independent experiments performed in triplicate. 
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DISCUSSION 
The cytotoxicity of NO donors was described in different tumor cell lines, including ovarian 
cancer,
[28,29]
 lung carcinoma,
[30]
 breast adenocarcinoma,
[31]
 hepatocellular carcinoma
[32] 
neuroblastoma
[33]
 and squamous cell carcinoma of the head and neck.
[34] 
Such effects were 
associated with the inhibition of cell proliferation and induction of apoptosis.
[35] 
In B16-F10 
melanoma cells, organic nitrate NO donors inhibited their metastatic potential, and 
DETA/NO NO donors reversed the resistance to chemotherapeutic agents, including 
doxorubicin.
[36]
 Additionally, organic nitrate NO donors prevented the formation of 
melanoma cell lung nodes in a murine melanoma in vivo model.
[37]
 These reports suggest the 
therapeutic potential use of NO donor nanomaterials in many types of cancer antitumor 
chemotherapy, including melanoma. Here, a nanostructured system containing NO and S-
nitroso-MSA-CS exhibited cytotoxicity against B16-F10 melanoma cells with no significant 
cytotoxicity in normal melanocytes. 
The mechanisms of cell death elicited by NO donors depend on several factors, such 
as cell type and tumor stage. Sustained NO production could act as a pro-apoptotic signal by 
activating caspases
[38]
 through its effect on mitochondria
[39,40]
 or by upregulation of death 
receptor expression and their sensitization to death ligands, as Fas-L (Fas ligand), TRAIL 
(tumor necrosis factor–related apoptosis-inducing ligand) and TNF-α (tumor necrosis factor-
α).
[41] 
Our data demonstrated that the cytotoxicity induced by S-nitroso-MSA-CS in 
melanoma cells is through caspase-dependent apoptosis. 
It is well established that NO stimulates the soluble guanylyl cyclase resulting in an 
increase of intracellular cGMP,
[42]
 whereas cGMP phosphodiesterase leads to a decrease.
[43]
 
The cGMP phosphodiesterase inhibitor, MY-5445, increases the intracellular cGMP levels 
and thus mimics the NO effect,
[44] 
but it did not alter the cytotoxicity of S-nitroso-MSA-CS, 
as well as the NO scavenger PTIO, despite the detection of NO-protein adducts as discussed 
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below. These data suggest that these nanoparticles probably do not act as a NO releasing 
prodrug. 
Reactions between NO and −SH groups of protein cysteine residues lead to S-
nitrosylation, which is an important and reversible post-translational modification able to 
regulate the activity and function of many proteins and cellular processes.
[45]
 S-nitroso-MSA-
CS increased cysteine S-nitrosylation and tyrosine nitration in melanoma cells. Probably the 
S-nitroso groups of S-nitroso-MSA-CS were transferred directly to free thiol groups of 
proteins through S-(trans)nitrosylation. In agreement, the occurrence of S-(trans)nitrosylation 
without release of free NO by RSNOs was previously proposed.
[46]
 
It is well known that the oxidation of protein thiol groups in mitochondrial membranes 
is related to mitochondrial permeabilization and release of pro-apoptotic proteins to the 
cytosol, triggering cell death.
[47,48] 
S-nitrosylation induced by S-nitroso-MSA-CS in 
melanoma cells was accompanied by oxidative stress characterized by H2O2 and 
mitochondrial superoxide overproduction, and by nitration of cellular proteins. In this regard, 
mitochondrial dysfunctions elicited by NO donors associated with increased superoxide 
production have been described.
[49]
 Additionally, ruthenium nitrosyl complexes inhibited 
mitochondrial respiration in hepatocarcinoma cells, resulting in ATP depletion, ROS 
production, and cell death.
[50] 
Increased superoxide production in mitochondria may occur due 
to nitration and inactivation of manganese-dependent superoxide dismutase
[51]
 and/or 
inhibition of the respiratory chain.
[52]
 These superoxide can react with NO generating 
peroxynitrite that nitrates –OH groups in tyrosine residues irreversibly, and the adduct 3-
nitrotyrosine is widely used as a nitrosative stress marker.
[53]
 
In summary, we presented here the cytotoxic effects of S-nitroso-MSA-CS on B16-
F10 melanoma cells. Such effects were selective to tumor cells when compared to normal 
melanocytes and dependent on the entire nanoparticle composition; only CS, free MSA or 
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free S-nitroso-MSA did not exhibit significant cytotoxicity. Additionally, the investigation of 
molecular mechanisms of cytotoxicity revealed that S-nitroso-MSA-CS induced an apoptotic 
cell death profile, dependent on caspase activation, and associated with a cellular and 
mitochondrial oxidative stress. Together these results point to the potential use of S-nitroso-
MSA-CS as an antitumor chemotherapy of melanoma. 
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